A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

Amgen

Status: Completed

Conditions: Atherosclerotic Cardiovascular Disease

Treatments: Other: Lp(a) Screening

Study type: Interventional

Funder types: Industry

Identifiers

NCT05378529

20210057

Details and patient eligibility

About

The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold:

• Evaluate the distribution of Lp(a) value in the overall participants with documented history of ASCVD
• Evaluate the distribution of Lp(a) value in participants with documented history of ASCVD by demographics and regions

Enrollment: 39,480 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent
• History of ASCVD

Exclusion criteria

• Participants known to be currently receiving investigational drug in a clinical study
• Participants with a diagnosis of end-stage renal disease or requiring dialysis
• Participants who have received lipoprotein apheresis to reduce Lp(a) within 3 months prior to enrollment

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

39,480 participants in 1 patient group

Participants with history of ASCVD

Other group

Description:

Participants with history of ASCVD with known or unknown Lp(a) values.

Treatment:

Other: Lp(a) Screening